Good morning, myeloma world.

We have a slightly different edition of Myeloma Morning cooked up for you today than is usually the case. Although we have one new myeloma research study that we will review – see the discussion further below about Cometriq – we will spend most of today's edition looking in more detail at an issue discussed in this Monday's edition of Myeloma Morning.

In that article, we discussed a recent study by physicians at the …

Good morning, myeloma world.

It's a glorious spring morning here at Myeloma Morning Headquarters. The sun is coming up in the midst of a clear blue sky, and the cherry tree out front is bursting with blossoms.

In other words, it's a great day to get excited about new multiple myeloma research and other myeloma-related developments.

First, we take a look at a new study by researchers at the John Theurer Cancer Center (JTCC) in New Jersey. They examine whether …

Good morning, myeloma world.

We hope your week is getting off to a good start. We've got a couple of new research studies to discuss in today's edition of Myeloma Morning, as well as several highlights from the Beacon's discussion forum.

On the research front, we'll start today by mentioning an article by physicians at the Mayo Clinic's Arizona campus. They report on a com­pli­ca­tion, known as thrombotic microangiopathy (TMA), that occurred in two multiple myeloma patients they …

Good morning, myeloma world.

We hope this Sunday edition of Myeloma Morning finds you rested and ready to do some quick myeloma-related catching up.

We always enjoy reporting on potential new myeloma ther­a­pies, so we thought we'd start today's update with a look at a new study by Korean researchers work­ing at LG Life Sciences. The researchers report results of preclinical (laboratory) tests they have carried out on two drugs, codenamed LC53-0110 and LC53-0151 (full text: html, pdf). …

Good morning, myeloma world.

We hope your weekend has gotten off to a good start. We've been looking over the latest myeloma-related research since the last edition of Myeloma Morning, and it appears we have just a short list of new material to discuss today.

In fact, we will be focusing today on just two new research articles.

The first is from a team of U.S. researchers, most of whom are based at the Uni­versity of Arkansas …

Good morning, myeloma world.

We have got quite an eclectic mix of myeloma-related research to report on today, ranging from a couple of lengthy review articles to a short case report.

Speaking of case reports, there are several of them, and we'll start with an unusual one. It's from a group of physicians at a hospital in Milan, Italy. They report on a patient with light chain monoclonal gammopathy who tested positive – incorrectly – on a standard test used …

Good morning, myeloma world.

After a particularly busy inaugural edition of Myeloma Morning, today's edition doesn't have quite as much ground to cover. We'll be focusing most of today's discussion on just four new research studies that have been published.

That being said, the first of those studies is going to require more than the usual amount of attention.

That's because the study is a new International Myeloma Working Group (IMWG) consensus state­ment concerning high-risk cytogenetics – …